Application of elastase inhibitor in preparation of medicine for treating cerebral perfusion insufficiency

By using elastase inhibitors such as civirestat, the activity and expression of NE under insufficient brain perfusion was inhibited, and the white matter damage and cognitive dysfunction caused by insufficient brain perfusion were solved, and the survival of oligodendrocytes was significantly improved. rate and brain function.

CN119074712AActive Publication Date: 2024-12-06BEIJING TIANTAN HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV

Patent Information

Application Number
CN202411269986.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-11
Publication Date
2024-12-06
Estimated Expiration
2044-09-11

AI Technical Summary

Technical Problem

Inadequate understanding of the pathogenesis of white matter damage and cognitive dysfunction caused by insufficient brain perfusion has hindered the development of new therapeutic drugs, especially in the injuries caused by insufficient brain perfusion, and there is a lack of effective treatment plans.

Method used

Elastase inhibitors, especially neutrophil elastase inhibitors, such as civerestat, are used to inhibit the activity and expression of elastase, reduce oligodendrocyte damage and enzyme cleavage of myelin protein CNPase. This inhibits white matter lesions.

Benefits of technology

Effectively inhibited the expression and activity of NE, alleviated oligodendrocyte damage and myelin damage, significantly improved the survival rate of oligodendrocytes, improved the behavioral results after brain insufficiency, and reduced white matter lesions .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074712A_ABST
    Figure CN119074712A_ABST
Patent Text Reader

Abstract

The invention relates to the field of medicine, in particular to application of an elastase inhibitor in preparation of a medicine for treating cerebral perfusion insufficiency. Research finds that the expression quantity of NE in the corpus callosum of a patient suffering from cerebral perfusion insufficiency is increased, NE can cause brain oligodendrocyte damage and white matter lesion, and the elastase inhibitor can effectively inhibit the expression quantity and activity of NE, relieve oligodendrocyte damage and relieve the enzyme digestion effect of NE on myelin CNPase at the same time, so that the corpus callosum in the patient suffering from cerebral perfusion insufficiency can be effectively inhibited, and the corpus callosum in the patient suffering from cerebral perfusion insufficiency can be effectively inhibited. The myelin sheath injury of the corpus callosum region is reduced, so that white matter lesion is inhibited.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates to a new medical application field of elastase inhibitors, and in particular to the application of elastase inhibitors in preparing drugs for treating cerebral hypoperfusion. Background Art

[0002] White matter lesion (WML) caused by cerebral hypoperfusion can damage sensory motor and cognitive functions, and induce oligodendrocyte apoptosis and myelin degeneration. Neutrophile elastase (NE) is a serine protease that can degrade foreign microorganisms or organic molecules phagocytosed by neutrophils. However, brain injury causes neutrophils to enter the brain tissue and release NE, degrading a variety of structurally and functionally important molecules in the brain tissue, destroying the blood-brain barrier and participating in the inflammatory response of brain injury, inducing neuronal death, and mediating inflammation-related secondary glial scar formation in spinal cord injury models. However, the pathogenesis of white matter lesions and cognitive dysfunction caused by cerebral hypoperfusion is currently insufficiently understood, which greatly hinders the development of new therapeutic drugs. Therefore, it is urgent to find new mechanisms that cause oligodendrocyte injury and white matter lesions and to develop related applications of existing drugs. Summary of the invention

[0003] Elastase inhibitors inhibit the activity and production of elastase. Currently, elastase inhibitors, especially neutrophil elastase inhibitors, have shown tissue protective effects in lung injury, pancreatitis, and nephritis. However, there are no reports on their use in the treatment of damage caused by cerebral hypoperfusion. In order to solve the above technical problems, the present disclosure provides the use of elastase inhibitors in the preparation of drugs for treating cerebral hypoperfusion.

[0004] The present disclosure provides the use of an elastase inhibitor in preparing a drug for treating brain white matter damage and / or oligodendrocyte damage.

[0005] The present disclosure provides the use of an elastase inhibitor in preparing a drug for treating vascular dementia.

[0006] As a preferred technical solution of the present disclosure, an elastase inhibitor is used in the preparation of a drug for inhibiting the enzymatic hydrolysis of myelin protein CNPase caused by NE.

[0007] As a preferred technical solution of the present disclosure, the elastase inhibitor includes sivelestat.

[0008] As a preferred technical solution of the present disclosure, the drug preparation is a lyophilized powder or an injection.

[0009] As a preferred technical solution of the present disclosure, the preparation further includes one or more pharmaceutically acceptable carriers or excipients.

[0010] As a preferred technical solution of the present disclosure, the pharmaceutically acceptable excipients include solubilizers, cosolvents, emulsifiers, flavoring agents, olfactory agents, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, pH regulators, stabilizers, diluents, glidants, surfactants or preservatives. One or more.

[0011] Compared with the prior art, the technical solution provided by the embodiments of the present disclosure has the following advantages:

[0012] The disclosed examples have been studied and found that the expression of NE in the corpus callosum of patients with cerebral hypoperfusion is increased, and NE can cause brain oligodendrocyte damage and white matter lesions. Elastase inhibitors can effectively inhibit the expression and activity of NE, reduce oligodendrocyte damage, and at the same time reduce the enzymatic cleavage of NE on the myelin protein CNPase, reduce myelin damage in the corpus callosum, and thus inhibit white matter lesions. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments consistent with the present disclosure and, together with the description, serve to explain the principles of the present disclosure.

[0014] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, for ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0015] Figure 1 The NE in the corpus callosum of one of the human specimens in the control group and one of the patients with cerebral small vessel disease (CSVD) in the embodiment of the disclosure is shown in FIG. + Staining images of cells.

[0016] Figure 2 for Figure 1 NE in the corpus callosum of human specimens from the control group + Cells and Figure 1 NE in the corpus callosum of patients with midbrain small vessel disease (CSVD) + Quantitative plots of cells.

[0017] Figure 3The NE protein concentration in the corpus callosum of the sham-operated control group mice and the CSVD white matter damage group mice caused by bilateral common carotid artery stenosis (BCAS) was evaluated by enzyme-linked immunosorbent assay at different time points in the embodiments of the present disclosure.

[0018] Figure 4 This is a graph showing the NE catalytic activity in corpus callosum homogenate samples of sham-operated control group mice and BCAS-induced CSVD white matter damage group mice at different time points determined by spectrophotometry in the embodiments of the present disclosure.

[0019] Figure 5 Representative optical microscope images and quantitative graphs of active cells after oligodendrocyte precursor cells (OPC) were treated with different concentrations of NE in the embodiments of the present disclosure.

[0020] Figure 6 Representative optical microscope images and quantitative graphs of active cells after OPC cells were treated with 40 nmol / L NE at different time points in the embodiments of the present disclosure.

[0021] Figure 7 In the embodiment of the present disclosure, A2B5 positively labeled OPC cells were treated with solvent and NE for 5 hours, and caspase-3 + (CC3 + ) Representative confocal images and quantitative plots of cells.

[0022] Figure 8 The graph is a quantitative graph of active cells in differentiated mature oligodendrocytes treated with different concentrations of NE according to the embodiment of the present disclosure.

[0023] Fig. 9 In the embodiment of the present disclosure, CC3 in differentiated mature oligodendrocytes treated with solvent and NE respectively + Representative confocal images and quantification of cells.

[0024] Fig.10 CNPase + Representative confocal images and quantitative plots of cells in NG2-positive OPC cells.

[0025] Fig.11 Representative confocal images of mature oligodendrocytes differentiated from the present invention were treated with solvent and NE for 5 hours, respectively, and then labeled with MBP and CNPase, as well as quantitative graphs of the mean fluorescence intensity of CNPase staining.

[0026] Fig.12This is a diagram of the domain structure of the CNPase protein of the disclosed embodiment.

[0027] Fig.13 This is a diagram of the protease cleavage products after recombinant human CNPase was cleaved with human natural NE under different enzyme and substrate (i.e., NE and CNPase) mass ratios (right) and different enzyme cleavage times (left) evaluated by SDS-PAGE and Coomassie Brilliant Blue staining in the embodiments of the present disclosure.

[0028] Fig.14 The NE cleavage site map and sequence amino acid conservation in the human CNPase protein and mouse CNPase protein of the embodiments of the present disclosure are shown.

[0029] Fig.15 These are representative images of the mouse corpus callosum stained with MBP, LFB and Olig2 in the sham operation control group, the model group solvent administration control group, the model group low-dose administration group and the model group high-dose administration group 30 days after surgery in the disclosed embodiments.

[0030] Fig.16 This is a quantitative graph of the average fluorescence intensity of MBP in the corpus callosum of mice in the sham operation control group, the model group solvent administration control group, the model group low-dose administration group, and the model group high-dose administration group 30 days after surgery in the examples of the present disclosure.

[0031] Fig.17 This is a diagram showing the extent of LFB-stained white matter lesions in the corpus callosum of mice in the sham operation control group, the model group solvent administration control group, the model group low-dose administration group, and the model group high-dose administration group 30 days after surgery in the examples of the present disclosure.

[0032] Fig.18 The expression of Olig2 in the corpus callosum of mice in the sham operation group, the model group solvent administration control group, the model group low-dose administration group and the model group high-dose administration group 30 days after surgery in the disclosed embodiment + Quantitative plots of cells.

[0033] Fig.19 This is an electron micrograph of representative myelin sheaths in the corpus callosum of mice in the sham operation control group, the model group solvent administration control group, the model group low-dose administration group, and the model group high-dose administration group 30 days after surgery in the examples of the present disclosure.

[0034] Fig. 20 This is a quantitative analysis graph of the g-ratio values ​​of nerve fibers (axons + myelin sheaths) in the corpus callosum of mice in the sham operation control group, the model group solvent administration control group, the model group low-dose administration group, and the model group high-dose administration group 30 days after surgery in the embodiments of the present disclosure.

[0035] Fig.21This is a scatter plot of the functional relationship between the g-ratio values ​​and axon diameters of the mice in the sham operation control group, the model group solvent administration control group, and the model group high-dose administration group 30 days after surgery in the disclosed embodiment.

[0036] Fig. 22 This is a graph of the axon diameters of mice in the sham operation control group, the model group solvent administration control group, the model group low-dose administration group, and the model group high-dose administration group 30 days after surgery in the examples of the present disclosure.

[0037] Fig.23 This is a graph showing the results of the rotarod fatigue test of mice in the sham operation control group, the model group solvent administration control group, the model group low-dose administration group, and the model group high-dose administration group at different time points in the embodiments of the present disclosure.

[0038] Fig.24 This is a graph showing the results of object recognition testing of mice in the sham operation control group, the model group solvent administration control group, the model group low-dose administration group, and the model group high-dose administration group 28 days after surgery in the embodiments of the present disclosure.

[0039] Fig.25 This is a graph showing the results of a Y-maze test on mice in the sham operation control group, the model group solvent administration control group, the model group low-dose administration group, and the model group high-dose administration group 29 days after surgery in the disclosed embodiments. DETAILED DESCRIPTION

[0040] In order to more clearly understand the above-mentioned objectives, features and advantages of the present disclosure, the scheme of the present disclosure will be further described below. It should be noted that the embodiments of the present disclosure and the features in the embodiments can be combined with each other without conflict.

[0041] In the following description, many specific details are set forth to facilitate a full understanding of the present disclosure, but the present disclosure may also be implemented in other ways different from those described herein; it is obvious that the embodiments in the specification are only part of the embodiments of the present disclosure, rather than all of the embodiments.

[0042] The disclosed embodiments propose the use of elastase inhibitors in the preparation of drugs for treating cerebral hypoperfusion. Studies have found that inhibiting NE by administering elastase inhibitors can significantly increase the survival rate of oligodendrocyte lineages, reduce the progression of white matter damage, and bring lasting improvements to behavioral outcomes after hypoperfusion injury.

[0043] The second aspect of the disclosed embodiments further proposes the use of an elastase inhibitor in the preparation of a drug for treating brain white matter damage and / or oligodendrocyte damage.

[0044] The third aspect of the disclosed embodiments further proposes the use of an elastase inhibitor in the preparation of a drug for treating vascular dementia.

[0045] The fourth aspect of the present disclosure further proposes the use of an elastase inhibitor in the preparation of a drug for inhibiting the enzymatic degradation of myelin protein CNPase caused by NE.

[0046] As a preferred implementation of the embodiments of the present disclosure, the elastase inhibitor includes sivelestat.

[0047] In some specific embodiments, the drug is administered by one of the approaches including: intravenous administration, intraperitoneal administration, intracoronary administration, intraarterial administration, intradermal administration, subcutaneous administration, transdermal delivery, intratracheal administration, intraarticular administration, intraventricular administration, skull administration, inhalation, intracerebral administration, umbilical, oral administration, intraocular administration, pulmonary administration, catheter injection, by suppository and direct injection into tissue. In addition, coloring agents, preservatives, spices, flavoring agents or other additives may also be added to the pharmaceutical preparations as needed. To achieve the purpose of medication and enhance the therapeutic effect, the drug or pharmaceutical composition of the present disclosure may be administered by any known method of administration.

[0048] The embodiments of the present disclosure will be described in detail below in conjunction with the examples, but those skilled in the art will appreciate that the following examples are only used to illustrate the present disclosure and should not be considered to limit the scope of the present disclosure. If no specific conditions are specified in the examples, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be obtained commercially.

[0049] Example:

[0050] 1. Human specimens and experimental methods

[0051] 1. Human specimens

[0052] Human sample collection was performed according to a protocol approved by the Institutional Review Board of Beijing Tiantan Hospital (Beijing, China). For immunostaining of human brain tissues, 3 control human brain sections and 8 CSVD human brain sections were included. The control brain tissues were obtained from deceased individuals with non-neurological diseases and no history of neuropsychiatric disorders.

[0053] 2. Experimental methods

[0054] Human brain sections of 5 μm thickness were cut and immunostained with NE antibody (ab68672, purchased from Abcam). Five randomly selected microscopic fields in the corpus callosum of each brain slide were examined, and the corpus callosum 0.15 mm 2 NE in the field of vision +Cells. The researchers were unaware of the clinical diagnosis when examining the samples. There was no statistically significant difference in the mean age between the CSVD group and the control group [CSVD group: 57.7 years ± 2.19 years; control group: 61.8 years ± 3.42 years; mean ± SEM; P > 0.05; unpaired t test].

[0055] 2. Animal Experiments

[0056] 1. Experimental animals: Male C57BL / 6 mice (purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd.), 8 weeks old, were randomly divided into 4 groups, 7 mice in each group, namely:

[0057] Sham group: received sham surgery;

[0058] Model group: solvent administration control group (BCAS+Vehicle): PBS buffer (Biosharp, cat No. BL302A, purchased from Beijing Lanjieke Technology Co., Ltd.) was administered after modeling;

[0059] Model group low-dose administration group (BCAS+Sivelestat, L): After modeling, a 1 mg / kg concentration of Sivelestat drug preparation (ONO-5046, catalog#3535, purchased from Tocris Bioscience) was administered; wherein, L stands for Low.

[0060] Model group high-dose administration group (BCAS+Sivelestat, H): After modeling, a 10 mg / kg sivelestat drug preparation was administered; wherein, H stands for High.

[0061] 2. Animal experimental methods:

[0062] 2.1BCAS model establishment:

[0063] The mice were anesthetized with 4.0% isoflurane and maintained in a system of 70% N2O and 30% O2 using 1.5% isoflurane. After a midline incision in the mouse neck, both common carotid arteries were exposed. A microcoil with a diameter of 0.18 mm (purchased from Wuxi Samini Spring Co., Ltd.) was surgically implanted into the bilateral common carotid arteries of the mice. The rectal temperature of the mice was maintained between 36.5°C and 37.5°C.

[0064] 2.2 Sham operation method: The specific operation was the same as that of the experimental group, but the surgery only exposed both common carotid arteries and no microcoil was implanted.

[0065] 3. Dosage method:

[0066] Sham control group (Sham): no reagent was given;

[0067] Model group solvent administration control group (BCAS+Vehicle): After successful modeling, 100 μL of PBS buffer was administered intraperitoneally once a day for 4 weeks;

[0068] Model group low-dose administration group (BCAS+Sivelestat, L): 100 μL of 1 mg / kg sivelestat drug preparation was administered once 24 h before BCAS surgery; after successful modeling, 100 μL of 1 mg / kg sivelestat drug preparation was administered once a day, all by intraperitoneal injection, for 4 weeks;

[0069] Model group high-dose administration group (BCAS+Sivelestat, H): 100 μL of 10 mg / kg sivelestat drug preparation was administered once 24 h before BCAS surgery; after successful modeling, 100 μL of 10 mg / kg sivelestat drug preparation was administered once a day, both by intraperitoneal injection, for 4 weeks.

[0070] It should be noted that the injection was stopped after 4 weeks (i.e., 28 days) in the model group solvent administration control group, the model group low-dose administration group, and the model group high-dose administration group. Although the administration was not continued on the 29th and 30th days after surgery, it did not affect the experimental test results.

[0071] 4. Experimental methods:

[0072] (2) New object recognition test: In order to evaluate non-spatial working memory, an object recognition test was performed. On the 28th day after surgery, the mice were placed in a box of 30 cm × 30 cm × 30 cm, and two trials were conducted with an interval of 6 hours. In the first trial, two identical objects were placed in the box, and the mice were allowed to interact freely with the objects for 10 minutes. Interaction was recorded when the mouse's nose was <1 cm away from the object. In the second trial, any of the objects was replaced with a new object, and the mouse explored the test area again for 10 minutes. The test result is the percentage of time spent exploring the new object to the total time spent exploring the old object and the new object.

[0073] (3) Y-maze test: 29 days after surgery, in order to evaluate the spatial working memory of mice, a Y-maze spontaneous change test was performed using a plastic Y-shaped runway. The Y-shaped runway has three identical arms (40 cm long, 12 cm high, and 3 cm wide), with a 120° angle between two adjacent arms. The arm in which the mouse was initially placed was marked A, and the other two arms were marked B and C, respectively. The experiment allowed the mouse to freely explore the Y-maze for 10 minutes, and the total number and order of the mouse entering each arm were recorded with a video camera. Among them, the number of spontaneous alternations refers to the total number of times the mouse completed any of the six routes of ABC, ACB, BAC, BCA, CAB, and CBA; the total number of arm entries refers to the total number of times the mouse entered all individual arms of the Y-maze.

[0074] Spontaneous alternation rate (%) = spontaneous alternation times / (total arm entry times - 2) × 100%

[0075] Mice with fewer than 15 total arm entries during the test period were excluded.

[0076] (4) Rotarod fatigue test: The mice were allowed to run on a rotating rod, starting at 5 rpm and accelerating to 40 rpm within 120 seconds, and then kept at 40 rpm for 5 minutes. Four groups of mice were tested at 3 and 4 weeks after surgery. Three consecutive tests were performed on each mouse each time, with an interval of 15 minutes. The time the mouse stayed on the rotating rod was recorded. The average of the three tests was calculated.

[0077] (5) Transmission electron microscopy was used to measure the thickness of myelin sheath in the corpus callosum. The specific operation was as follows: 30 days after surgery, the mice were deeply anesthetized and the brain tissue was perfused with 4% PFA containing 2.5% glutaraldehyde. The brain tissue was cut into 1 mm thick brain slices using a mouse coronal slice mold. On this basis, 1 mm thick slices of the left corpus callosum were extracted from 0.5 mm behind the anterior bregma. 3 As samples. All samples were post-fixed in osmium tetroxide, dehydrated through gradient concentrations of ethanol, pre-embedded in propylene oxide, and flat-embedded in epoxy resin to obtain test samples. The test samples were observed by conventional transmission electron microscopy and examined under an electron microscope at 120 kV. Three to five images were collected at a magnification of 50,000 in randomly selected areas in the corpus callosum, and the inner and outer circumferences of the myelin sheaths of more than 50 axons per animal were analyzed by ImageJ software by researchers who were blind to the experimental groups. The g-ratio is the ratio of the inner diameter to the outer diameter of the axon of each axon fiber.

[0078] (6) Luxol Fast Blue Stain (LFB): LFB staining is used to detect myelin changes in white matter areas. The commercial Luxol Fast Blue Stain (myelin stain) kit (ab150675, purchased from Abcam) was used according to the instructions to stain the myelin sheath in the corpus callosum region of mouse brain slices. TM The white matter lesions in the corpus callosum were observed under a VS200 microscope and quantitatively analyzed using Image J software.

[0079] (7) Immunohistochemistry and image analysis: Prepare frozen sections of brain tissue, and use the bleaching method to stain the MBP and olig2 regions of the mouse brain corpus callosum. Transfer 20 μm thick brain sections to a 24-well plate containing PBS buffer, rinse 3 times with PBS buffer, dry the liquid, add the primary antibody, and incubate in a 4°C refrigerator for 16 hours. Wash the brain sections incubated with the primary antibody 5 times with PBS buffer, then incubate them with the fluorescently conjugated secondary antibody at room temperature for 1 hour, and then mount them on a glass slide with a mounting medium containing the nuclear staining reagent 4',6-diamidino-2-phenylindole (DAPI) (ab104139, purchased from Abcam). The primary and secondary antibodies used in this test method are shown in Table 1:

[0080] Table 1

[0081]

[0082] Images were collected using an Akoya Phenolmager HT fully automated quantitative pathology imager and analyzed using ImageJ software.

[0083] (8) Enzyme-linked immunosorbent assay (ELISA): A commercial ELISA kit (MELA20, purchased from R&D Systems) was used to measure the NE content in the corpus callosum of mice. The corpus callosum tissue of mice was minced, added with 50 μL PBS, and the brain tissue was ground using a sample grinder (Jing N9548 Intelligent Model, Beijing Hede Technology Co., Ltd.), and the cells were ultrasonically lysed with an ultrasonic cell crusher (JY92-IIN, Ningbo Xinzhi Biotechnology Co., Ltd.), and centrifuged at 500 g for 15 minutes at 4°C. After centrifugation, the supernatant sample was obtained, and the supernatant was added to the ELISA kit and the NE content in the corpus callosum of mice was determined according to the instructions.

[0084] (9) NE activity assay: The NE catalytic activity was determined using the synthetic substrate N-methoxysuccinyl-Ala-Ala-Pro-Val p-nitroanilide (M4765, purchased from Sigma). The reaction system for the NE enzyme activity assay included 1 mmol / L substrate, 0.5 mol / L NaCl solution, and 0.1 mol / L Tris-HCl buffer (pH 8.0). The corpus callosum tissue homogenate sample was added to the NE enzyme activity assay reaction system and incubated at 37°C for 24 hours. After incubation, the amount of p-nitroaniline released (representing NE activity) was measured spectrophotometrically at 405 nm.

[0085] (10) Analysis of enzyme cleavage sites, N-terminal dimethyl labeling and mass spectrometry: Recombinant human CNPase (aa 1-421, MBS1475160, purchased from MyBioSource, 4 μg) was mixed with human natural NE (SE563, purchased from Elastin products, 0.25 μg) and incubated at 37°C for 2 hours. The reaction was then terminated by adding SDS-PAGE denaturing protein loading buffer (B1012-5, purchased from Beijing Prilai Gene Technology Co., Ltd.) and boiling to obtain the protease digestion product. The protease digestion product was sent to Beijing Biotech Biotechnology Co., Ltd. for dimethyl labeling and analyzed by liquid chromatography-tandem mass spectrometry (LC-MS / MS) to obtain the raw file of the mass spectrometry original result. The human CNPase data (P09543) was matched in the UniProt database by the Byonic software to obtain the identification result.

[0086] (11) Tissue dissociation and cell separation: Weigh and enzymatically digest the brain tissue of newborn C57BL / 6 mice according to the instructions of the Mouse Neural Tissue Dissociation Kit (130-092-628, purchased from Miltenyi Biotec). The dissociated tissue was passed through a 100 μm cell strainer (BD Bioscience) and centrifuged at 300 g for 10 minutes at room temperature to obtain a cell pellet. The cell pellet was resuspended in D-PBS buffer (D8537, purchased from Sigma). Mouse oligodendrocyte precursor cells (OPCs) were enriched using the CD140α (PDGFRα) microbead kit (130-101-502, purchased from Miltenyi Biotec). The sorted OPCs were verified by immunofluorescence staining for cell-specific markers.

[0087] (12) Primary culture and treatment of oligodendrocyte precursor cells (OPCs) and differentiated oligodendrocytes: Primary OPCs were obtained from C57BL / 6 mouse pups using a CD140a (PDGFRα) microbead kit (130-101-502, purchased from Miltenyi Biotec) according to the manufacturer's protocol. Primary OPCs were seeded onto poly-D-lysine / laminin-coated coverslips and expanded in growth medium for 3 days before the experiment. The growth medium was neurobasal medium (A2477501, purchased from Gibco) containing 2% B27 supplement (17504044, purchased from Gibco), 10 ng / mL PDGF-AA (100-13A, purchased from PeproTech), 10 ng / mL CNTF (450-50, purchased from PeproTech), and 1 ng / mL NT3 (450-03, purchased from PeproTech).

[0088] The OPCs obtained in the growth medium were differentiated for 6 days using differentiation medium, with half of the medium replaced every 2 days. The differentiation medium was neurobasal medium containing 2% B27 supplement, 5 μg / mL insulin (I2643, purchased from Sigma-Aldrich), 40 ng / ml triiodothyronine (T3) (T6397, purchased from Sigma-Aldrich) and 10 ng / ml CNTF.

[0089] (13) Coomassie Brilliant Blue Staining: The protein product of CNPase (aa 1-421, MBS1475160, purchased from MyBioSource, 4 μg) cleaved by NE (SE563, purchased from Elastin Products, 0.25 μg) was subjected to SDS-PAGE electrophoresis and then stained with Coomassie Brilliant Blue. The number and position of bands on the SDS-PAGE gel after Coomassie Brilliant Blue staining were used to determine the cleavage of CNPase by NE.

[0090] (14) Cell immunofluorescence staining: OPC cells were inoculated into a 24-well plate with slides one day in advance. On the second day, staining was started when the OPC cells were fused to about 70%. Specifically, the cells were fixed with 4% paraformaldehyde (PFA), then rinsed with PBS buffer for 3 times, and after absorbing the liquid, the primary antibody was added and incubated in a 4°C refrigerator for 16 hours; then washed with PBS buffer for 5 times, and the fluorescently conjugated secondary antibody was added and incubated at room temperature for 1 hour, and the glass slide was sealed onto a glass slide using a sealing agent. The primary and secondary antibodies used in this test method are shown in Table 2:

[0091] Table 2

[0092]

[0093] Images were captured using a Zeiss LSM 710 confocal laser scanning microscope and analyzed using ImageJ software.

[0094] 5. Experimental results

[0095] 5.1NE expression increases in the corpus callosum of patients and mice after chronic hypoperfusion

[0096] About human specimens:

[0097] in, Figure 1 The NE in the corpus callosum of one of the human specimens in the control group and one of the patients with cerebral small vessel disease (CSVD) in the embodiment of the disclosure is shown in FIG. + The right side of the image of the CSVD group is the enlarged image in the white box, showing the NE + Cell.

[0098] Figure 2 for Figure 1 NE in the corpus callosum of human specimens from the control group + Cells and Figure 1 NE in the corpus callosum of patients with midbrain small vessel disease (CSVD) + Quantitative plots of cells.

[0099] from Figure 1 and Figure 2 It can be seen that regarding human specimens, the abundance of NE in the corpus callosum of patients with cerebral small vessel disease (CSVD) is significantly higher than that of human specimens from the control group.

[0100] About experimental mice:

[0101] Figure 3 The NE protein concentration in the corpus callosum of the sham-operated control group mice and the CSVD white matter damage disease group mice caused by bilateral common carotid artery stenosis (BCAS) was evaluated by enzyme-linked immunosorbent assay at different time points in the disclosed embodiments. Specifically, the CSVD white matter damage disease group mice caused by BCAS were not injected with any reagent.

[0102] Figure 4 This is a graph showing the NE catalytic activity in corpus callosum homogenate samples of sham-operated control group mice and BCAS-induced CSVD white matter damage group mice at different time points determined by spectrophotometry in the embodiments of the present disclosure.

[0103] Depend on Figure 3and Figure 4 It can be seen that compared with the sham-operated mice, the NE protein concentration and NE catalytic activity in the corpus callosum of mice in the BCAS-induced chronic hypoperfusion white matter injury disease group increased significantly 3 days after surgery and reached a peak 28 days after surgery.

[0104] 5.2NE induces oligodendrocyte precursor cell (OPC) and oligodendrocyte cell death in vitro

[0105] in, Figure 5 The representative optical microscope images and quantitative graphs of active cells after oligodendrocyte precursor cells (OPC) were treated with different concentrations of NE in the embodiments of the present disclosure, wherein 0 nM represents treatment with only solvent, and the solvent is 0.9% NaCl solution.

[0106] Figure 6 Representative optical microscope images and quantitative graphs of active cells after OPC cells were treated with 40 nmol / L NE at different time points in the embodiments of the present disclosure.

[0107] like Figure 5 and Figure 6 As shown, compared with the vehicle-treated group (ie, the control group), NE-treated oligodendrocyte precursors significantly reduced the number of OPC cells in a dose-dependent and time-dependent manner.

[0108] Figure 7 In the embodiment of the present disclosure, A2B5 positively labeled OPC cells were treated with solvent and NE for 5 hours, and caspase-3 + (CC3 + ) Representative confocal images and quantitative graphs of cells. The solvent was 0.9% NaCl solution.

[0109] Figure 8 The graph is a quantitative graph of active cells in differentiated mature oligodendrocytes treated with different concentrations of NE according to the embodiment of the present disclosure.

[0110] Fig. 9 In the embodiment of the present disclosure, CC3 in differentiated mature oligodendrocytes treated with solvent and NE respectively + Representative confocal images and quantitative plots of cells. The solvent was 0.9% NaCl solution.

[0111] Depend on Figure 8 It can be seen that compared with the solvent-treated group, the number of mature oligodendrocytes decreased in a concentration-dependent manner after NE treatment for 24 hours. Figure 7 and Fig. 9 The immunostaining results showed that compared with the solvent-treated group, CC3 +The apoptotic cell counts increased significantly, providing evidence that NE induces apoptosis in OPCs and mature oligodendrocytes.

[0112] 5.3NE's enzymatic cleavage effect on CNPase.

[0113] in, Fig.10 CNPase + Representative confocal images and quantitative plots of cells in NG2-positive OPC cells.

[0114] Fig.11 Representative confocal images of mature oligodendrocytes differentiated from the present disclosure were treated with solvent and NE for 5 hours, and then labeled with MBP and CNPase, and a quantitative graph of the average fluorescence intensity of CNPase staining, wherein the solvent was 0.9% NaCl solution.

[0115] like Fig.10 and Fig.11 As shown, the CNPase protein levels in both OPCs and mature oligodendrocytes were significantly decreased after NE treatment compared with the vehicle-treated group.

[0116] Fig.12 This is a diagram of the domain structure of the CNPase protein of the disclosed embodiment.

[0117] from Fig.12 It can be seen that CNPase consists of a polynucleotide kinase domain, a phosphodiesterase domain, and a C-terminal extension. In addition, subtype II contains an N-terminal mitochondrial targeting sequence (MTS, marked as M in the figure), which is removed after mitochondrial import; PNK is a polynucleotide kinase; 2H refers to the phosphodiesterase domain consisting of two conserved histidine residues; C is a C-terminal extension.

[0118] Fig.13 This is a diagram of the protease cleavage products after recombinant human CNPase was cleaved with human natural NE under different enzyme and substrate (i.e., NE and CNPase) mass ratios (right) and different enzyme cleavage times (left) evaluated by SDS-PAGE and Coomassie Brilliant Blue staining in the embodiments of the present disclosure.

[0119] Fig.14 The NE cleavage site map and sequence amino acid conservation in the human CNPase protein and mouse CNPase protein of the embodiments of the present disclosure are shown.

[0120] from Fig.13 and Fig.14As can be seen, 11 primary cleavage sites were identified in human CNPase through N-terminal sequencing and mass spectrometry analysis. These sites are all located in the conserved 2H phosphodiesterase domain and are highly consistent with the NE cleavage site specificity recorded in the MEROPS database.

[0121] 5.4 Effects of sivelestat on histopathology, nerve fiber integrity, and neurological function.

[0122] in, Fig.15 These are representative images of the mouse corpus callosum stained with MBP, LFB and Olig2 in the sham operation control group, the model group solvent administration control group, the model group low-dose administration group and the model group high-dose administration group 30 days after surgery in the disclosed embodiments.

[0123] Fig.16 This is a quantitative graph of the average fluorescence intensity of MBP in the corpus callosum of mice in the sham operation control group, the model group solvent administration control group, the model group low-dose administration group, and the model group high-dose administration group 30 days after surgery in the examples of the present disclosure.

[0124] Fig.17 This is a diagram showing the extent of LFB-stained white matter lesions in the corpus callosum of mice in the sham operation control group, the model group solvent administration control group, the model group low-dose administration group, and the model group high-dose administration group 30 days after surgery in the examples of the present disclosure.

[0125] Fig.18 The expression of Olig2 in the corpus callosum of mice in the sham operation group, the model group solvent administration control group, the model group low-dose administration group and the model group high-dose administration group 30 days after surgery in the disclosed embodiment + Quantitative plots of cells.

[0126] from Figure 15-18 It can be seen that compared with the sham operation control group, the MBP fluorescence intensity of the mice in the model group solvent administration control group was significantly reduced, the white matter integrity was destroyed, and the number of oligodendrocytes in the corpus callosum was reduced; while these symptoms of the mice in the model group low-dose administration group and the model group high-dose administration group were alleviated, and the efficacy of the high-dose group was more obvious. This shows that treatment with sivelestat can indeed reduce white matter lesions and oligodendrocyte reduction caused by cerebral hypoperfusion.

[0127] Fig.19 This is an electron micrograph of representative myelin sheaths in the corpus callosum of mice in the sham operation control group, the model group solvent administration control group, the model group low-dose administration group, and the model group high-dose administration group 30 days after surgery in the examples of the present disclosure.

[0128] from Fig.19It can be seen that the myelin sheath of the mice in the sham operation control group remained intact with clear boundaries, while the myelin sheath of the mice in the solvent administration control group of the model group was severely damaged, with vacuoles and stratification (as shown by the red arrow).

[0129] Fig. 20 This is a quantitative analysis graph of the g-ratio values ​​of nerve fibers (axons + myelin sheaths) in the corpus callosum of mice in the sham operation control group, the model group solvent administration control group, the model group low-dose administration group, and the model group high-dose administration group 30 days after surgery in the embodiments of the present disclosure.

[0130] Fig.21 This is a scatter plot of the functional relationship between the g-ratio values ​​and axon diameters of the mice in the sham operation control group, the model group solvent administration control group, and the model group high-dose administration group 30 days after surgery in the disclosed embodiment.

[0131] Fig. 22 This is a graph of the axon diameters of mice in the sham operation control group, the model group solvent administration control group, the model group low-dose administration group, and the model group high-dose administration group 30 days after surgery in the examples of the present disclosure.

[0132] like Figure 20-Figure 22 As shown, while there was no significant change in the axon diameter of all groups of mice, the g-ratio of the myelin sheath of the model group solvent-administered control group mice increased compared with the sham-operated control group, indicating that the BCAS disease model leads to a decrease in the thickness of the myelin sheath. Compared with the model group solvent-administered control group, the g-ratio of the myelin sheath of BCAS mice treated with sivelestat was significantly reduced, and the g-ratio of the high-dose administration group of the model group was closer to the sham-operated group. Fig.19 It can also be clearly seen that the myelin integrity of mice in the high-dose drug group of the model group was better, indicating that inhibiting NE with sivelestat can indeed reduce the myelin damage of nerve fibers after cerebral hypoperfusion.

[0133] Fig.23 This is a graph showing the results of the rotarod fatigue test of mice in the sham operation control group, the model group solvent administration control group, the model group low-dose administration group, and the model group high-dose administration group at different time points in the embodiments of the present disclosure.

[0134] like Fig.23 As shown, in the rotarod fatigue test, the time that the model group solvent-administered control group mice stayed on the rotating rod was greatly reduced compared with the sham-operated control group mice. Compared with the model group solvent-administered control group mice, mice treated with sivelestat showed dose-dependent improvements in motor balance function, with statistically significant improvements at a high dose of 10 mg / kg.

[0135] Fig.24This is a graph showing the results of object recognition testing of mice in the sham operation control group, the model group solvent administration control group, the model group low-dose administration group, and the model group high-dose administration group 28 days after surgery in the embodiments of the present disclosure.

[0136] like Fig.24 As shown, in the novel object recognition test, the exploratory preference for novel objects in the vehicle-administered control group mice of the model group after training was significantly reduced compared with that in the sham-operated control group mice, and this reduction was improved in a dose-dependent manner in mice treated with sivelestat.

[0137] Fig.25 This is a graph showing the results of a Y-maze test on mice in the sham operation control group, the model group solvent administration control group, the model group low-dose administration group, and the model group high-dose administration group 29 days after surgery in the disclosed embodiments.

[0138] like Fig.25 As shown in the Y-maze test, 10 mg / kg sivelestat treatment can significantly restore the short-term spatial working memory function of BCAS mice, indicating that sivelestat can indeed partially reverse the effects of cerebral hypoperfusion on neurological function.

[0139] It should be noted that, in this article, relational terms such as "first" and "second" are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprise" or any other variants thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or device. In the absence of further restrictions, the elements defined by the sentence "comprise a ..." do not exclude the existence of other identical elements in the process, method, article or device including the elements.

[0140] The above description is only a specific embodiment of the present disclosure, so that those skilled in the art can understand or implement the present disclosure. Various modifications to these embodiments will be apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present disclosure. Therefore, the present disclosure will not be limited to the embodiments described herein, but will conform to the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. Application of elastase inhibitors in the preparation of drugs for treating cerebral hypoperfusion.

2. Use of elastase inhibitors in the preparation of drugs for treating brain white matter damage and / or oligodendrocyte damage.

3. Application of elastase inhibitors in the preparation of drugs for the treatment of vascular dementia.

4. The use of elastase inhibitors in the preparation of drugs for inhibiting the enzymatic hydrolysis of myelin protein CNPase caused by NE.

5. The use according to any one of claims 1 to 4, wherein the elastase inhibitor comprises sivelestat.

6. The use according to any one of claims 1 to 4, characterized in that: The dosage form of the drug is lyophilized powder or injection.

7. The use according to any one of claims 1 to 4, characterized in that: The medicine also includes one or more pharmaceutically acceptable carriers or excipients.

8. The use according to claim 7, characterized in that: The pharmaceutically acceptable excipients include one or more of solubilizers, cosolvents, emulsifiers, flavoring agents, olfactory agents, colorants, binders, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, pH regulators, stabilizers, diluents, glidants, surfactants or preservatives.

Citation Information

Patent Citations

  • Use of elastic protease inhibitor for preparing medicine for protecting cerebral hemorrhage

    CN1813706A

Cited By

  • Application of Alvelestat in preparation of medicine for treating cerebral hemorrhage

    CN122163604A